Joseph Thome
Stock Analyst at TD Cowen
(2.27)
# 3,343
Out of 5,182 analysts
24
Total ratings
47.62%
Success rate
0.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Thome
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MPLT MapLight Therapeutics | Initiates: Buy | n/a | $30.31 | - | 1 | Apr 7, 2026 | |
| UTHR United Therapeutics | Maintains: Buy | $575 → $660 | $569.11 | +15.97% | 4 | Mar 30, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $117 → $125 | $94.06 | +32.89% | 3 | Mar 27, 2026 | |
| PTCT PTC Therapeutics | Maintains: Hold | $50 → $63 | $70.26 | -10.33% | 3 | Nov 5, 2025 | |
| ARDX Ardelyx | Maintains: Buy | $9 → $10 | $5.97 | +67.50% | 1 | Oct 31, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Buy | n/a | $88.99 | - | 1 | May 13, 2025 | |
| VRDN Viridian Therapeutics | Initiates: Buy | n/a | $13.61 | - | 1 | Nov 25, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | n/a | $33.74 | - | 1 | Jul 2, 2024 | |
| ALKS Alkermes | Initiates: Buy | $34 | $34.14 | -0.41% | 1 | Jun 17, 2024 | |
| PRME Prime Medicine | Initiates: Buy | n/a | $3.69 | - | 1 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.44 | - | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $54.53 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.90 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $130 | $185.00 | -29.73% | 2 | Jun 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $13.20 | - | 1 | Jan 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $12.89 | - | 1 | Nov 23, 2021 |
MapLight Therapeutics
Apr 7, 2026
Initiates: Buy
Price Target: n/a
Current: $30.31
Upside: -
United Therapeutics
Mar 30, 2026
Maintains: Buy
Price Target: $575 → $660
Current: $569.11
Upside: +15.97%
Mirum Pharmaceuticals
Mar 27, 2026
Maintains: Buy
Price Target: $117 → $125
Current: $94.06
Upside: +32.89%
PTC Therapeutics
Nov 5, 2025
Maintains: Hold
Price Target: $50 → $63
Current: $70.26
Upside: -10.33%
Ardelyx
Oct 31, 2025
Maintains: Buy
Price Target: $9 → $10
Current: $5.97
Upside: +67.50%
Bright Minds Biosciences
May 13, 2025
Initiates: Buy
Price Target: n/a
Current: $88.99
Upside: -
Viridian Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: n/a
Current: $13.61
Upside: -
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: n/a
Current: $33.74
Upside: -
Alkermes
Jun 17, 2024
Initiates: Buy
Price Target: $34
Current: $34.14
Upside: -0.41%
Prime Medicine
Apr 8, 2024
Initiates: Buy
Price Target: n/a
Current: $3.69
Upside: -
Mar 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.44
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $54.53
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.90
Upside: -
Jun 29, 2022
Maintains: Outperform
Price Target: $120 → $130
Current: $185.00
Upside: -29.73%
Jan 31, 2022
Initiates: Outperform
Price Target: n/a
Current: $13.20
Upside: -
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $12.89
Upside: -